Imaging Center COE

A Study Evaluating Optimal Use of Radioactive Drugs for Prostate Cancer Therapy - Misha Beltran

Details
Misha Beltran shares details on the Department of Defense grant, a collaboration with Scott Tagawa and Neil Bander at Weill Cornell, and now a continuing effort at the Dana-Farber Cancer Institute. This grant is providing funding to really hone in on the therapeutic side of who are the patients most likely to benefit from PSMA scanning. Focusing on better treatment options for these patients and w...

PSMA Theranostics and Personalized Prostate Cancer Care- Frankis Almaguel

Details
Frankis Almaguel, MD joins Phillip Koo, MD for the ongoing lecture series that is sponsored by the Society of Nuclear Medicine and Molecular Imaging (SNMMI). Dr. Almaguel speaks to the current state of PSMA theranostics in the care of patients with prostate cancer. Molecular imaging is dependent on biomarkers. These biomarkers are the key to identifying cancer cells within the normal tissue. Preci...

Focal Therapy - Art Rastinehad

Details
Art Rastinehad provides insight into the role of focal therapy in the treatment of prostate cancer. He begins the presentation with the evolution of prostate cancer care. He describes focal therapy in the context of the next significant opportunity in the treatment of prostate cancer once we have a positive biopsy and walks us through the why, the who the how and the where in defining focal therap...

Prostate Cancer Diagnosis and Treatment: Incorporating New PET imaging and Theranostic Approaches - Robert Flavell

Details
Phillip Koo hosts a lecture series which is being developed by the Prostate Cancer Outreach Working Group of the SNMMI. The Prostate Cancer Outreach Working Group focuses on increasing awareness of oncologists, urologists, and family practitioners about imaging and therapy technologies such as FACBC, bone scintigraphy, and radium-223. This lecture series will cover the complete spectrum of prostat...

Advancements in PSMA PET/CT Imaging - Phil Koo and Jeremie Calais

Details
Nuclear Medicine physician at UCLA, Jeremie Calais joins Phillip Koo in discussion on PSMA based PET imaging, the state of the field at his facility, UCLA, advancements in previous years, and they take a deeper dive into the diagnostic and therapeutic setting of PSMA imaging and the outlook in the new year. Biographies: Jeremie Calais, MD, MSc Assistant Professor at the Ahmanson Translational Imag...

Theranostic Approaches for Advanced Prostate Cancer - Michael Hofman

Details
Charles Ryan and Michael Hofman share in a discussion on the use of new imaging techniques in prostate cancer, the sensitivity of imaging and the use of theranostics PSMA targeted therapies for metastatic castrate-resistant prostate cancer. Michael Hofman details the quick advance of PSMA imaging in Australia. He highlights PSMA tracers including Gallium-68 and PSMA-Based [18F]DCFPyL PET/CT and th...

3D Prostate Gland Uptake of 18F Choline PET CT - Association with Overall Survival in Patients with Hormone-naive Prostate Cancer - May Sadik

Details
Dr. May Sadik presents data from the SNMMI meeting highlighting a retrospective study in 45 patients with hormone naïve prostate cancer. The objective was to develop a completely automated method to quantify prostate gland update of 18F-choline in PET/CT images. The hope is that these preliminary data will lead to a better understanding of the relationship between this measure, the clinical data a...

Introducing TIN 117m for Convention Electron Therapy of mCRPC - Suresh Srivastava

Details
Suresh C. Srivastava presents the unique opportunities and future for nuclear medicine, including theragnostic radiopharmaceuticals for molecular imaging plus therapy and getting closer to personalized medicine, selection criteria, production, and the nuclear, physical, and chemical properties of certain dual-purpose radionuclides, including those that are currently being used, or studied and eval...

18F Fluorocholine PET-Whole Body MR in the Staging of High Risk Prostate Cancer - Ur Metser

Details
Ur Metser a study that was conducted to determine whether integrated 18F-fluorocholine (FCH) PET whole-body MRI (PET/WBMRI) depicts lymph node and distant metastases in patients with high-risk prostate cancer more frequently than does conventional staging. Biography: Ur Metser, MD, FRCPC, Joint Department of Medical Imaging, the University of Toronto Related Content: 18F-Fluorocholine PET Whole-Bo...

68Ga PSMA 11 PET MRI in Intermediate and High Risk Prostate Cancer - Claudia Zacharias

Details
Claudia Zacharias presents Gallium 6 PSMA-11 PET/MR Imaging in Patients with Newly Diagnosed Intermediate- or High-Risk Prostate Cancer, a pilot study evaluating the detection rate for the initial diagnosis of prostate cancer and the metastatic spread for patients in the intermediate and high-risk prostate cancer risk category using 68 Ga-PSMA-11 PET/MR. She reviews the potential role of 68 Ga-PSM...